US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
United Therapeutics Corporation - Common Stock
(NQ:
UTHR
)
541.70
-29.68 (-5.19%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about United Therapeutics Corporation - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
17
18
Next >
3 Reasons Investors Love United Therapeutics (UTHR)
April 17, 2026
Since April 2021, the S&P 500 has delivered a total return of 68.6%. But one standout stock has more than doubled the market - over the past five years, Unit...
Via
StockStory
Topics
Stocks
United Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for miroliverELAP® for Treatment of Acute Liver Failure
April 08, 2026
From
United Therapeutics Corporation
Via
Business Wire
3 Market-Beating Stocks for Long-Term Investors
April 07, 2026
Stocks that outperform the market usually share key traits such as rising sales, expanding margins, and increasing returns on capital. The select few that ca...
Via
StockStory
Topics
Energy
United Therapeutics Surges 14% on Groundbreaking Tyvaso Phase 3 Results for IPF
March 31, 2026
In a landmark moment for respiratory medicine and biotechnology, United Therapeutics (NASDAQ:UTHR) announced late Monday, March 30, 2026, that its pivotal TETON-1 Phase 3 study for nebulized Tyvaso...
Via
MarketMinute
United Therapeutics Corp. (NASDAQ:UTHR) Emerges as a Peter Lynch-Style GARP Candidate
↗
March 28, 2026
Via
Chartmill
United Therapeutics Corp (NASDAQ:UTHR) Emerges as a Peter Lynch-Style GARP Candidate
↗
March 04, 2026
Via
Chartmill
Chips Down, Ackman Up: How Iran, the Fed, and a Viral Post Defined Monday's Market
↗
March 31, 2026
Via
Chartmill
Topics
Economy
Why United Therapeutics (UTHR) Stock Is Up Today
March 30, 2026
What Happened? Shares of biotechnology company United Therapeutics (NASDAQ:UTHR) jumped 12.7% in the afternoon session after the company announced its TETON-...
Via
StockStory
Traders are paying attention to the gapping stocks in Monday's session.
↗
March 30, 2026
Via
Chartmill
United Therapeutics Corporation Announces TETON-1 Pivotal Study of Tyvaso® Meets Primary Endpoint for Treatment of Idiopathic Pulmonary Fibrosis, Exceeding Impressive Treatment Effect Seen in TETON-2
March 30, 2026
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics Corp. (NASDAQ:UTHR) Reports Record Annual Revenue Despite Q4 Top-Line Miss
↗
February 25, 2026
Via
Chartmill
1 Surging Stock with Impressive Fundamentals and 2 That Underwhelm
March 30, 2026
Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements...
Via
StockStory
Therapeutics Stocks Q4 In Review: United Therapeutics (NASDAQ:UTHR) Vs Peers
March 23, 2026
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...
Via
StockStory
Topics
Artificial Intelligence
2 Mid-Cap Stocks for Long-Term Investors and 1 We Avoid
March 19, 2026
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the man...
Via
StockStory
1 Cash-Heavy Stock to Target This Week and 2 That Underwhelm
March 18, 2026
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face c...
Via
StockStory
Topics
Firearms
This Biotech Stock Surged 75% Last Quarter and Pulled a New $9 Million Investment
↗
March 16, 2026
Vera Therapeutics develops clinical-stage therapies for serious immunological diseases, with a lead candidate targeting kidney disorders.
Via
The Motley Fool
Topics
Regulatory Compliance
This Life Sciences Supplier Has Plunged 50% in a Year, but One Fund Bought Up $28 Million More in Stock
↗
March 16, 2026
Avantor delivers laboratory materials and specialized services to biopharma, healthcare, and advanced technology clients worldwide.
Via
The Motley Fool
Topics
Regulatory Compliance
Supply Chain
United Therapeutics Corporation Announces Full Results of TETON-2 Phase 3 Clinical Trial Published in The New England Journal of Medicine
March 11, 2026
From
United Therapeutics Corporation
Via
Business Wire
Winners And Losers Of Q4: Biogen (NASDAQ:BIIB) Vs The Rest Of The Therapeutics Stocks
March 09, 2026
Let’s dig into the relative performance of Biogen (NASDAQ:BIIB) and its peers as we unravel the now-completed Q4 therapeutics earnings season. Over the next ...
Via
StockStory
Topics
Artificial Intelligence
United Therapeutics Corporation Announces $2 Billion Stock Repurchase Authorization and Enters into $1.5 Billion Accelerated Share Repurchase Program
March 09, 2026
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics Corporation to Present at the Leerink Global Healthcare Conference
March 03, 2026
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics Corporation Announces Ralinepag Achieved 55% Reduction in Risk of Clinical Worsening in Pivotal Pulmonary Arterial Hypertension Study, Delivering Exceptional, Highly Statistically Significant Efficacy
March 02, 2026
From
United Therapeutics Corporation
Via
Business Wire
2 Cash-Producing Stocks to Keep an Eye On and 1 That Underwhelm
February 26, 2026
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Via
StockStory
Why United Therapeutics (UTHR) Shares Are Sliding Today
February 26, 2026
Shares of biotechnology company United Therapeutics (NASDAQ:UTHR) fell 7.2% in the afternoon session after the company reported fourth-quarter financial results that missed revenue expectations,...
Via
StockStory
Topics
Earnings
The Moonshot Medicine: United Therapeutics Surges on Record Earnings and TreSMI Breakthrough
February 26, 2026
United Therapeutics Corporation (Nasdaq: UTHR) has long been a favorite of biotech investors who value both steady cash flows and visionary "moonshot" projects. On February 25, 2026, the company...
Via
Finterra
Topics
Earnings
Economy
Intellectual Property
United Therapeutics (UTHR) Deep Dive: Strong Q4 and the ‘Inhalation Evolution’
February 26, 2026
As of February 26, 2026, United Therapeutics Corporation (NASDAQ: UTHR) stands at a pivotal crossroads in the biotechnology sector. Long recognized as a dominant force in the treatment of pulmonary...
Via
Finterra
Topics
Artificial Intelligence
Economy
Intellectual Property
MannKind Stock Plummets After Partner United Therapeutics Unveils New ‘Category Killer Product’
↗
February 25, 2026
United Therapeutics unveiled a new product called Tresmi, which is “a proprietary drug device formulation of treprostinil into a soft mist inhaler.”
Via
Stocktwits
United Therapeutics (NASDAQ:UTHR) Misses Q4 CY2025 Revenue Estimates
February 25, 2026
Biotechnology company United Therapeutics (NASDAQ:UTHR) missed Wall Street’s revenue expectations in Q4 CY2025, but sales rose 7.4% year on year to $790.2 million. Its GAAP profit of $7.70 per share...
Via
StockStory
United Therapeutics Corporation Reports Fourth Quarter and Full Year 2025 Financial Results
February 25, 2026
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics (UTHR) Q4 Earnings Report Preview: What To Look For
February 23, 2026
Biotechnology company United Therapeutics (NASDAQ:UTHR) will be reporting earnings this Wednesday before the bell. Here’s what to expect.
Via
StockStory
Topics
Artificial Intelligence
< Previous
1
2
3
4
5
6
7
8
9
...
17
18
Next >
